Kala reaches deal to sell Eysuvis, Inveltys to Alcon
May 23, 2022
According to the companies, Kala will receive $60 million in upfront payment, and could be eligible to receive additional sales-based milestone payments.
© 2022 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
Dry Eye
Aerie Pharmaceuticals doses first participant in COMET-2 study of dry eye candidate
May 24, 2022
The Phase 3 registrational study is examining AR-15512, a differentiated, novel product candidate for the treatment of the signs and symptoms of Dry Eye Disease
Dry eye disease associated with Sjögren’s syndrome: Cost of treatment a factor
May 17, 2022
In a paper, investigators identified strategies used by patients to reduce the cost of therapy and its impact on adherence to treatment Patients may be reluctant to disclose challenges regarding adherence to dry eye disease therapy, as well as fears of worsening quality of life.
Companies forge partnership to develop treatment option for dry eye syndrome
May 17, 2022
BRIM Biotechnology Inc. has entered into a new strategic partnership with Ora Inc. for the late-stage clinical development of lead drug candidate BRM421 for dry eye syndrome (DES).
Use of CO-02 to stimulate the trigeminal nerve is a reasonable mechanism to help treat dry eyes
May 11, 2022
The study's primary endpoints were to look at increasing Schirmer's scores, as well as eye discomfort score.
Study evaluates OC-01 (varenicline solution) as a treatment for symptoms and signs of dry eye
May 11, 2022
Takeaway: there doesn't seem to be a specific dry eye phenotype that does better or worse.
Bringing biologics to eye health
May 10, 2022
Ophthalmologists, optometrists gain nonpharmacological treatment options for some of the eye’s most complex issues, providing better outcomes.
Eyes with ocular involvement from SJS/TEN mandate acute and chronic care
May 09, 2022
Patients are at risk for developing severe dry eye and ocular surface disease.
Aerie Pharmaceuticals continues their work in dry eye and glaucoma markets
May 03, 2022
Michelle Senchyna, PhD, VP Clinical Development and Medical Affairs for Aerie Pharmaceuticals, gives a company update on the various clinical trials in the pipeline.
Investigators outline relationship between dry eye disease and high myopia in teenagers
May 02, 2022
In a poster presented at the Association for Research in Vision and Ophthalmology’s 2022 annual meeting in Denver, Osama Ibrahim Hirayama, MD, and colleagues offered results that demonstrating that anisometropia and astigmatic error were greater among the patients with high myopia compared with the other groups. Compared with the subjects with no myopia, those with high myopia reported significantly more dryness, less photophobia, and less pain.
Latest News
Understanding the biological causes and cell types that lead to one of the leading causes of irreversible blindness worldwide could benefit treatment in patients
Aerie Pharmaceuticals doses first participant in COMET-2 study of dry eye candidate
Technology, people key to improving health outcomes, driving revenue